Actavis will become Allergan to emphasize branded pharma focus
This article was originally published in Scrip
Two years and three names later, Actavis will reinforce its branded pharmaceuticals-led growth strategy by changing its name to Allergan when the company's $66bn acquisition of the Botox (onabotulinumtoxinA) maker closes within the next month or two.
You may also be interested in...
Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.
Allergan generated enough cash flow in the first quarter to justify increased spending to develop and promote new products in 2017 – reinvesting because it can, not necessarily because it has to.
PhRMA CEO Stephen Ubl visited Allergan's Irvine, Calif. R&D and manufacturing campus as the trade association continues its "Go Boldly" campaign promoting biopharma innovation in an effort to counteract the hit the industry's reputation has taken from drug pricing concerns.